31 completed. 31 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 31 |
| Phase 2 | 9 | Completed 9 |
Follow Phobic Disorders: new trials by email Literature Review of Phobic Disorders trials Research Report on Phobic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Centanafadine, Placebo - ADHD, Anxiety | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 315 | 2025-03-26 | 2026-05-06 |
| Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 225 mg BNC210, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Bionomics Limited | 370 | 2024-08-06 | 2026-05-19 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 224 | 2021-05-24 | 2025-09-12 |
| Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety | Phase 2 / Phase 3 | Completed | Yale University | 22 | 2017-01-01 | 2021-05-20 |
| Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) PH94B, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Pherin Pharmaceuticals, Inc. | 23 | 2014-03-01 | 2015-12-07 |
| Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Virtual Reality Exposure Therapy (VRET) - Phobic Disorders | Phase 2 / Phase 3 | Completed | VU University of Amsterdam | 56 | 2013-03-01 | 2015-07-08 |
| Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Computerized Cognitive Behavioral Therapy, Treatment as usual - Generalized Anxiety Disorder, Social Phobia | Phase 3 | Completed | University of South Florida | 100 | 2011-08-01 | 2019-06-18 |
| Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Cognitive-behavioral therapy, Treatment as Usual - Autism, Asperger's Syndrome | Phase 2 / Phase 3 | Completed | University of South Florida | 45 | 2010-04-01 | 2013-04-02 |
| D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Individual Cognitive Behavioral Therapy (CBT), D-Cycloserine, Placebo - Phobic Disorders | Phase 3 | Completed | Southern Methodist University | 40 | 2010-04-01 | 2013-02-21 |
| Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Group Cognitive Behavioral Therapy, Yohimbine Hydrochloride, Sugar Pill - Social Anxiety Disorder | Phase 3 | Completed | Southern Methodist University | 40 | 2009-03-01 | 2013-11-11 |
| Flushing in Social Anxiety Disorder on Seroquel Seroquel, Sugar Pill - Social Anxiety Disorder | Phase 3 | Completed | START Clinic for Mood and Anxiety Disorders | 21 | 2008-10-01 | 2014-02-25 |
| Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Virtual Reality Exposure Therapy - Phobic Disorders | Phase 2 / Phase 3 | Completed | VU University of Amsterdam | 67 | 2008-07-01 | 2018-09-13 |
| A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Cognitive Behavioral Therapy Group, Vocational Services as Usual - Social Anxiety Disorder | Phase 2 / Phase 3 | Completed | University of Michigan | 165 | 2008-04-01 | 2012-07-31 |
| Treatment of Social Phobia and Panic Disorder in Adults individual cognitive-behavioural therapy, stepped care model - Social Phobia, Panic Disorder | Phase 3 | Completed | Haukeland University Hospital | 174 | 2008-03-01 | 2016-01-26 |
| Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia D-cycloserine, Cognitive behavioral therapy (CBT), Placebo - Social Anxiety Disorder | Phase 3 | Completed | Boston University Charles River Campus | 169 | 2007-12-01 | 2019-02-26 |
| A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy CBT via the Internet, CBT group therapy - Social Phobia | Phase 3 | Completed | Karolinska Institutet | 128 | 2007-11-01 | 2010-10-26 |
| A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder Namenda/Memantine - General Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Completed | State University of New York - Upstate Medical University | 15 | 2006-12-01 | 2014-12-10 |
| Comparison of Psychotherapy Programs to Treat Panic Disorder Cognitive behavioral therapy, Applied relaxation training (ART), Panic focused psychodynamic psychotherapy (PFPP) - Anxiety Disorders, Panic Disorder | Phase 3 | Completed | Weill Medical College of Cornell University | 201 | 2006-09-01 | 2022-12-23 |
| Social Anxiety Disorder Study Of Paroxetine Paroxetine hydrochloride hydrate - Social Phobia | Phase 3 | Completed | GlaxoSmithKline | 390 | 2005-12-01 | 2013-04-15 |
| Long-term Study Of Paroxetine in Women and Men BRL29060A, paroxetine hydrochloride hydrate - Social Phobia | Phase 3 | Completed | GlaxoSmithKline | 50 | 2005-10-01 | 2013-04-15 |
Showing 20 of 31. Sign in to see all of them.
Phobia, Social (25) · Anxiety Disorders (14) · Generalized Anxiety Disorder (7) · Anxiety, Separation (4) · Panic Disorder (3) · Acrophobia (2) · Aerophobia (2) · Agoraphobia (2) · Disease (2) · Obsessive-Compulsive Disorder (2) · Asperger Syndrome (1) · Attention Deficit Disorder with Hyperactivity (1) · Autistic Disorder (1) · Mental Disorders (1)
Mental Disorders (30) · Anxiety Disorders (17) · Neurodevelopmental Disorders (6) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · Attention Deficit and Disruptive Behavior Disorders (1) · Autism Spectrum Disorder (1) · Behavior (1) · Child Development Disorders, Pervasive (1) · Communication Disorders (1) · Disease Attributes (1) · Language Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1)
Cognitive Behavioral Therapy (7) · Sugars (3) · Cycloserine (2) · Paroxetine (2) · Quetiapine Fumarate (2) · Therapeutics (2) · Virtual Reality Exposure Therapy (2) · Counseling (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · Fluoxetine (1) · Fluvoxamine (1) · Hypericum extract LI 160 (1) · Memantine (1) · Psychotherapy (1)
GlaxoSmithKline (2) · Southern Methodist University (2) · University of South Florida (2) · VU University of Amsterdam (2) · Bionomics Limited (1) · Boston University Charles River Campus (1) · Connor, Kathryn M., M.D. (1) · Duke University (1) · Haukeland University Hospital (1) · Johns Hopkins University (1) · Karolinska Institutet (1) · Massachusetts General Hospital (1) · Modum Bad (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · National Institute of Mental Health (NIMH) (1)
United States (20) · Japan (2) · Netherlands (2) · Norway (2) · Canada (1) · Puerto Rico (1) · Sweden (1)
Eric A Storch, Ph.D. (2) · Jasper Smits, Ph.D. (2) · Asle Hoffart, Dr Psychol (1) · Barbara Milrod, MD (1) · David H Barlow, PhD (1) · Finn-Magnus Borge, Cand Psychol (1) · Jack Gorman, MD (1) · Jacques P. Barber, PhD (1) · Jasper A. Smits, PhD (1) · Jonathan Davidson, M.D. (1) · Joseph Himle, PhD (1) · Katherine H. Shear, MD (1) · Kathryn M. Connor, M.D. (1) · Laurence Greenhill, MD (1)
PMID 18030084, PMID 18974308, PMID 20013046, PMID 20051130, PMID 20206470, PMID 21391024, PMID 21483704, PMID 22122292, PMID 22320999, PMID 23098672, PMID 23332511, PMID 23357440, PMID 24129543, PMID 24237691, PMID 24260145, PMID 24417601, PMID 24477837, PMID 24565357, PMID 24610431, PMID 25461793, PMID 25721183, PMID 26081010, PMID 26366886, PMID 26663632, PMID 26708332, PMID 27464313, PMID 27561175, PMID 28735699, PMID 28956620, PMID 29336228, PMID 29877727, PMID 29960692, PMID 30256548, PMID 30773148, PMID 30821630, PMID 30869969, PMID 30906874, PMID 31471911, PMID 32105128, PMID 32584211, PMID 33705168, PMID 36479955, PMID 37861988, PMID 38217328, PMID 41773906
R01MH045963 (1), R01MH045964 (1), R01MH045965 (1), R01MH045966 (1), R01MH053703 (1), R01MH064481 (1), R01MH064726 (1), R01MH070664 (1), R01MH075889 (1), R01MH078308 (1), U01MH064089 (1)